​

Jade Biosciences (JBIO) Stock Forecast, Price Target & Predictions

OverviewOwnershipChart

JBIO Stock Forecast

Jade Biosciences (JBIO) stock forecast, based on 4 Wall Street analysts, predicts a 12-month average price target of $44.33, with a high of $55.00 and a low of $34.00. This represents a 125.94% increase from the last price of $19.62.

JBIO Stock Rating

Jade Biosciences stock's rating consensus is Buy, based on 4 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 4 Buy (100.00%), 0 Hold (0.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 4 0 4 Strong Sell Sell Hold Buy Strong Buy

JBIO Price Target Upside V Benchmarks

TypeNameUpside
StockJade Biosciences125.94%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts-69
Avg Price Target-$43.00$39.00
Last Closing Price$19.62$19.62$19.62
Upside/Downside-119.16%98.78%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jul, 26-10---10
Jun, 26-9---9
May, 26-9---9
Apr, 26-9---9
Mar, 26-7---7
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Jun 15, 2026UBS$45.00$15.34193.35%129.36%
Jun 02, 2026Piper Sandler$55.00$18.59195.86%180.33%
Jun 02, 2026Vamil DivanGuggenheim$47.00$18.59152.82%139.55%
May 11, 2026Laura ChicoWedbush$34.00$25.8131.73%73.29%
May 11, 2026Guggenheim$32.00$25.8123.98%63.10%
Apr 27, 2026H.C. Wainwright$45.00$24.9880.14%129.36%
Mar 06, 2026Alex ThompsonStifel Nicolaus$40.00$14.07184.29%103.87%
Jan 07, 2026H.C. Wainwright$25.00$13.1789.83%27.42%
Oct 09, 2025BTIG$28.00$9.08208.37%42.71%
Jun 16, 2025Vamil DivanGuggenheim$14.00$6.76107.10%-28.64%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Jun 15, 2026UBSBuyinitialise
Jun 02, 2026H.C. WainwrightBuyBuyhold
Jun 02, 2026GuggenheimBuyBuyhold
Jun 01, 2026JefferiesBuyBuyhold
Jun 01, 2026BTIGBuyBuyhold
May 11, 2026WedbushOutperformOutperformhold
May 11, 2026GuggenheimBuyBuyhold
Apr 27, 2026H.C. WainwrightBuyBuyhold
Mar 25, 2026H.C. WainwrightBuyBuyhold
Jan 07, 2026H.C. WainwrightBuyinitialise

Financial Forecast

EPS Forecast

$-20 $-16 $-12 $-8 $-4 $0 Dec 24 Dec 25 Dec 26 Dec 27
Dec 24Dec 25Dec 26Dec 27
Reported$-18.79---
Avg Forecast$-18.79$-2.43$-1.96$-2.36
High Forecast$-18.79$-1.16$-1.67$-2.27
Low Forecast$-18.79$-3.09$-2.15$-2.45
Surprise %----

Revenue Forecast

Dec 24 Dec 25 Dec 26 Dec 27
Dec 24Dec 25Dec 26Dec 27
Reported----
Avg Forecast----
High Forecast----
Low Forecast----
Surprise %----

Net Income Forecast

$-95K $-77K $-59K $-41K $-23K $-5K Dec 24 Dec 25 Dec 26 Dec 27
Dec 24Dec 25Dec 26Dec 27
Reported$-93.96K---
Avg Forecast$-93.98K$-10.63K$-9.55K$-11.80K
High Forecast$-93.98K$-5.80K$-8.35K$-11.35K
Low Forecast$-93.98K$-15.45K$-10.75K$-12.25K
Surprise %-0.02%---

JBIO Forecast FAQ

Is Jade Biosciences stock a buy?

Jade Biosciences stock has a consensus rating of Buy, based on 4 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 4 Buy, 0 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Jade Biosciences is a favorable investment for most analysts.

What is Jade Biosciences's price target?

Jade Biosciences's price target, set by 4 Wall Street analysts, averages $44.33 over the next 12 months. The price target range spans from $34 at the low end to $55 at the high end, suggesting a potential 125.94% change from the previous closing price of $19.62.

How does Jade Biosciences stock forecast compare to its benchmarks?

Jade Biosciences's stock forecast shows a 125.94% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Jade Biosciences over the past three months?

  • July 2026: 0% Strong Buy, 100.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • June 2026: 0% Strong Buy, 100.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • May 2026: 0% Strong Buy, 100.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is Jade Biosciences’s EPS forecast?

Jade Biosciences's average annual EPS forecast for its fiscal year ending in December 2025 is $-2.43, marking a -87.07% decrease from the reported $-18.79 in 2024. Estimates for the following years are $-1.96 in 2026, and $-2.36 in 2027.

What is Jade Biosciences’s revenue forecast?

Jade Biosciences's average annual revenue forecast for its fiscal year ending in December 2025 is $0, reflecting a 0% decrease from the reported $0 in 2024. The forecast for 2026 is $0, and $0 for 2027.

What is Jade Biosciences’s net income forecast?

Jade Biosciences's net income forecast for the fiscal year ending in December 2025 stands at $-10.627K, representing a -88.69% decrease from the reported $-93.958K in 2024. Projections indicate $-9.552K in 2026, and $-11.802K in 2027.